Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05747560
Other study ID # Feng8898
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 20, 2023
Est. completion date December 30, 2023

Study information

Verified date March 2023
Source Zhejiang University
Contact Fengqin Feng, Dr
Phone +8613906504026
Email feng_fengqin@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With the increasing improvement of living standard, more and more people are concerned about the body height of their children. It has been reported that 542 out of 1000 children (54.2%) failed to meet the standards of height. Moreover, nearly 80% was disappointed with the height of their children. The body height of child is mainly influenced by 60% of genetic factors (6 out of 10) and 40% of acquired factors which includes nutrition, exercise, sleep, psychology, disease and so on. Therefore, it is an important way to solve the problem by regulating the acquired factors. At present, inject growth hormone (GH) for children is the main way to solve the problem of children's body weight. However, high price, complex operation skills, and side effects limits the implication of GH. Additionally, the effect of traditional Chinese medicine therapy, exercise therapy, and dietary supplement are of dubious benefit and without clinical support. Elevated insulin like growth factor-1 (IGF-1) levels in the human body have been recognized as one of the core criteria for evaluating body enhancement therapy. Currently, there is no dietary supplement intervention to enhance the sensitivity of GH receptor and IGF-1 receptor. The goal of this clinical trial is to test the effect of dietary supplements on height improvement in children (aged 8-15 years of both genders). The main question it aims to answer is: Study the effect of dietary supplements (a formula based on enhancing the sensitivity of GH receptor and IGF-1 receptor) on height improvement in children by. Participants will be randomly divided into three groups: Placebo, Astragalus extract, and Wolfiporia extract. 1. Participants in the Placebo will consume placebo (a look-alike substances that contains no active drug) at a dose of 500 mg, twice a day (morning and evening) for 6 months. Participants in the Astragalus extract will take dietary supplement with astragalus extract at a dose of 450 mg, twice a day for the same duration. Participants in the Wolfiporia extract will take dietary supplement with wolfiporia extract at a dose of 15 g, twice a day for the same duration. 2. Taken blood sample at the timepoint of baseline (Day 0), intermediate point (Day 90), intervention end point (Day 180)) to detect biochemical markers, as well as body height and weight, and skeletal age. 3. Throughout the trial, subjects were asked to keep their usual lifestyle, food, and physical exercise and not took any dietary supplements. Researchers will compare the effects of Placebo with Astragalus extract, placebo with Wolfiporia extract, and Astragalus extract with Wolfiporia extract to see if Astragalus extract and Wolfiporia extract increase children's height, and whether Astragalus extract or Wolfiporia extract is more works well.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 30, 2023
Est. primary completion date December 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 15 Years
Eligibility Inclusion Criteria: 1. Body height: from the 10th to the 75th; 2. Skeletal age: bone age and actual age ±1. Exclusion Criteria: 1. Treated with growth hormone; 2. Sexual precocity; 3. Abnormal liver and kidney function; 4. IGF levels: below -2SD and above +2SD; 5. IGF BP3 level: below -2SD; 6. Growth hormone deficiency; 7. Diagnosed genetic disease; 8. BMI: Underweight or obese; 9. Abnormal thyroid function.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Buckwheat
Take buckwheat at a dose of 500 mg twice a day for 6 months.
Astragalus extract
Take astragalus extract at a dose of 450 mg twice a day for 6 months.
Wolfiporia extract
Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.

Locations

Country Name City State
China College of Biosystems Engineering and Food Science Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline body height at 6 months Determination of the change of body height of the participants at 6 months. Baseline (Day 0), Intervention end point (Day 180)
Secondary Change from baseline skeletal age at 6 months Determination of the change of skeletal age of the participants at 6 months. Baseline (Day 0), Intervention end point (Day 180)
Secondary Change from baseline body weight at 6 months Determination of the change of body weight of the participants at 6 months. Baseline (Day 0), Intervention end point (Day 180)
See also
  Status Clinical Trial Phase
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Recruiting NCT04691349 - CAR-T for r/r Malignant Tumors in Children Early Phase 1
Not yet recruiting NCT06455592 - Effect of APA on Sleep Quality in Children With Cancer From 5 to 16 Years N/A
Not yet recruiting NCT05806983 - Evaluation of the Efficiency of the Technology-Based Psychosocial Empowerment Program Program N/A
Not yet recruiting NCT05566951 - Technology-Based Psychosocial Empowerment Program for Home Care of Children With Cancer and Their Parents N/A
Recruiting NCT05329467 - Validation of Pain Assessment Scale Faces Thermometer Scale (FTS) N/A
Not yet recruiting NCT04016506 - Epidemiology, Management and Complications Related to Pancreatic Trauma in Children
Recruiting NCT05761847 - Pediatric Medication Therapy Management Trial N/A
Not yet recruiting NCT06291012 - Stopping Pneumonia Antibiotherapy Regimen Early Phase 4
Not yet recruiting NCT05943587 - The Development and Evaluation of Pain Neuroscience Education in Children N/A
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function
Completed NCT04846400 - Pilot Study of a Self-Supporting Nasopharyngeal Airway in Hypotonia N/A
Completed NCT04040036 - Effects of Virtual Reality on Pain, Fear and Anxiety During Blood Draw in Children Aged 5-12 Years Old N/A
Completed NCT03312881 - Neuropathic Pain in Children: Multimodal Assessment and Diagnosis
Completed NCT04334733 - The Impact of Preprocedural Animation About Echocardiography Display and Kaleidoscope Display on Anxiety in Children N/A
Completed NCT06220383 - Evaluation of The Effect of Crowns Applied With Hall Technique on Occlusion N/A
Completed NCT03941392 - Nutritional Study in Spanish Pediatric Population
Completed NCT03244332 - HEMOCC Study. Hemostasis in Cirrhotic Children. N/A
Not yet recruiting NCT06299267 - The Effect of Dual Task on Manual Skill Performance in Children and Adolescents N/A
Active, not recruiting NCT04070131 - Horse Assisted Rehabilitation Postoncologic Treatment in Children and Adolescents: Physical and Psychological Effects N/A